SciVision Biotech : The The Company’s Product, hyaluronic acid three-injection linear intra-articular implant, Flexotron Plus (2%) has obtained medical device license.

Close

Today's Information

Provided by: SciVision Biotech Inc.
SEQ_NO	1	Date of announcement	2022/05/26	Time of announcement	18:24:12
Subject	The The Company's Product, hyaluronic acid three-injection linear intra-articular implant, Flexotron Plus (2%) has obtained medical device license.
Date of events	2022/05/26	To which item it meets	paragraph 51
Statement	1.Date of occurrence of the event:2022/05/26 2.Company name:SciVision Biotech Inc. 3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:Flexotron Plus (2%), a three-injection linear intra-articular implant of hyaluronic acid developed and produced by the company, has passed and obtained the medical device license (P3H 2022/17103). 6.Countermeasures:make this announcement 7.Any other matters that need to be specified:This product contains hyaluronic acid, which can increase joint lubrication and reduce joint friction.For the majority of patients with degenerative knee arthritis, it can inhibit the degeneration of cartilage, promote its metabolism, relieve pain and discomfort, improve daily activities and increase range of activities of joints. Russia has a population of 147 million, of which about 13% have osteoarthritis. The company has obtained the Russian national medical device license, for three-injection linear intra-articular implant,which can increase the sales performance in the Russian market and contribute to the company's revenue.